Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Fetal Diagn Ther ; 39(1): 56-63, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26314825

RESUMO

Reduced first-trimester concentrations of placental protein 13 (PP13) are associated with subsequent development of preeclampsia, a major pregnancy disorder. We previously showed that PP13 has a vasodilatory effect, reduces blood pressure and augments expansive remodeling of the uteroplacental vasculature in pregnant rats. In this study, slow-release osmotic pumps were implanted in gravid rats (on day 8) to provide 1 week of PP13 supplementation. Treatment was associated with a reversible blood pressure reduction that returned to normal on day 15. In addition, PP13 caused venous expansion that is larger in the venous branches closer to the placenta. Then, it increased placental and pup weights. Similar administration of a truncated PP13 variant (DelT221) that is unable to bind carbohydrates (a rare spontaneous mutation associated with a high frequency of severe early preeclampsia among Blacks in South Africa) produced a hypotensive effect similar to the full-length molecule, but without venous remodeling and increased placental and pup weights. These results indicate the importance of PP13 carbohydrate binding for inducing vascular remodeling and improving reproductive outcome. Future studies are needed to determine whether beneficial effects would be evident in animal models of preeclampsia or in women predisposed to the development of preeclampsia.


Assuntos
Peso ao Nascer/efeitos dos fármacos , Galectinas/farmacologia , Pré-Eclâmpsia/genética , Proteínas da Gravidez/farmacologia , Útero/efeitos dos fármacos , Remodelação Vascular/efeitos dos fármacos , Animais , Pressão Sanguínea/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos , Feminino , Desenvolvimento Fetal/efeitos dos fármacos , Galectinas/genética , Galectinas/uso terapêutico , Tamanho da Ninhada de Vivíparos/efeitos dos fármacos , Placenta/efeitos dos fármacos , Pré-Eclâmpsia/tratamento farmacológico , Gravidez , Proteínas da Gravidez/genética , Proteínas da Gravidez/uso terapêutico , Ratos Sprague-Dawley , Útero/irrigação sanguínea
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA